Search Result

Results for "

P300/CBP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Autophagy (1) E3 Ligase Ligand-Linker Conjugates (2) Epigenetic Reader Domain (36) HIF/HIF Prolyl-Hydroxylase (1) Histone Acetyltransferase (44) Histone Demethylase (1) Ligands for Target Protein for PROTAC (6) MDM-2/p53 (2) Molecular Glues (1) PROTACs (13) Wnt (2) β-catenin (2)
By Research Areas:	Cancer (73) Cardiovascular Disease (1) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (4)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-132197

CBP/p300-IN-12	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC₅₀ of 166 nM) and *CBP* inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC₅₀ of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .

HY-151812

CBP/p300-IN-20	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
CBP/p300-IN-20 is a potent and selective *p300/CBP* inhibitor, with a pIC₅₀ of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer .

HY-128876

CBP/p300-IN-3	Histone Acetyltransferase	Cancer
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1 .

HY-136920

CBP/p300-IN-8 1 Publications Verification	Epigenetic Reader Domain	Cancer
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC₅₀=0.01-0.1 µΜ) and BRD4 (IC₅₀=1-1000 µΜ) activity .

HY-139861

CBP/p300-IN-14	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-14 is a potent inhibitor of *CBP/EP300* (lysine acetyltransferase) with an IC₅₀ of 3.3 nM (extracted from patent WO2021213521A1, compound 27) .

HY-146277

CBP/p300-IN-19	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity .

HY-146277A

CBP/p300-IN-19 hydrochloride	Histone Acetyltransferase	Cancer
CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC₅₀s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 hydrochloride shows antitumor activity .

HY-155229

CBP/p300-IN-21	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-21 (Compound 5d) is a selective *CBP/p300* inhibitor (IC₅₀: 0.07 and 1.755 μM for p300 and CBP). CBP/p300-IN-21 decreases H3K18Ac level. CBP/p300-IN-21 inhibits growth of 4T1 tumor growth in mice .

HY-100132

CBP/p300-IN-5	Histone Acetyltransferase	Cancer
P300/CBP-IN-5 is a potent p300/CBP histone acetyltransferase inhibitor extracted from patent WO2016044770A1, Example 715, has an IC₅₀ of 18.8 nM .

HY-143339

CBP/p300-IN-15	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
CBP/p300-IN-15 (compound 13a) is a potent *p300/CBP* inhibitor, with IC₅₀ values of 2.50 and 28.0 nM, respectively. CBP/p300-IN-15 shows good activity against OVCAR-3 and A2780 cell line, with EC₅₀ values of 0.865 and 2.71 μM, respectively. CBP/p300-IN-15 can be used for ovarian cancer research .

HY-111420

CBP/p300-IN-1	Epigenetic Reader Domain	Cancer
CBP/p300-IN-1 is a *CBP/EP300* bromodomain inhibitor.

HY-138536

*PROTAC CBP/P300* Degrader-1** 1 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
PROTAC CBP/P300 Degrader-1 is a potent PROTAC CBP/P300 degrader. PROTAC CBP/P300 Degrader-1 potently inhibited cell viability of multiple cancer cell lines .

HY-161483

CBP/p300 ligand 3	Epigenetic Reader Domain Histone Acetyltransferase	Neurological Disease Cancer
CBP/p300 ligand 3 is a target protein ligand of CBPD-268 (HY-161369). *CBP* and *p300* are two proteins with histone acetyltransferase (HAT) activity, and *CBP* and *p300* play key roles in regulating biological processes such as gene expression, cell proliferation, differentiation and DNA repair. Through its acetyltransferase activity, *CBP/p300* can acetylate histones and other proteins, thereby regulating chromatin structure and gene expression. CBP/p300 ligand 3 regulates the function of *CBP/p300* by binding to a specific domain of the *CBP/p300* protein (the bromine domain or HAT domain), inhibiting its enzyme activity or altering its interactions with other proteins (transcription factors). CBP/p300 ligand 3 can be used in cancer, neurodegenerative diseases and other disease models associated with abnormal *CBP/p300* function .

HY-161495

CBP/p300 ligand 4	Ligands for Target Protein for PROTAC Epigenetic Reader Domain	Cancer
CBP/p300 ligand 4 (Compound 4) is an orally active inhibitor for CBP/p300 bromodomain, with IC₅₀ of 91.4 nM. CBP/p300 ligand 4 serves as a ligand for target protein XYD190 (HY-161495). XYD190 is a PROTAC degrader for CBP/p300 .

HY-128875

CBP/p300-IN-10	Histone Acetyltransferase	Cancer
CBP/p300-IN-10 is a highly potent histone acetyltransferase EP300 and CREBBP with IC₅₀ values of 26 nM and 39 nM, respectively. CBP/p300-IN-10 can be used to research anticancer .

HY-138539

CBP/p300 ligand 2	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 2 is a ligand for target protein for PROTAC of dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-161711

CBP/p300 ligand 5	Ligands for Target Protein for PROTAC	Cancer
CBP/p300 ligand 5 is the target protein ligand of XYD129 (HY-161710). CBP/p300 ligand 5 can be used to study the acute myelogenous leukemia .

HY-143441

CBP/p300-IN-17	Histone Acetyltransferase	Cancer
CBP/p300-IN-17 (compound 7) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.18, 0.69 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143442

CBP/p300-IN-18	Histone Acetyltransferase	Cancer
CBP/p300-IN-18 (compound 8) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.056, 0.46 µM for HAT EP300 and LK2 H3K27, respectively .

HY-143440

CBP/p300-IN-16	Histone Acetyltransferase	Cancer
CBP/p300-IN-16 (compound 1) is a potent EP300/CBP HAT inhibitor with IC₅₀s of 0.61, 2.24 µM for HAT EP300 and LK2 H3K27, respectively .

HY-139707

*Thalidomide-NH-CBP/p300* ligand 2**	PROTACs Molecular Glues Epigenetic Reader Domain	Cancer
Thalidomide-NH-CBP/p300 ligand 2 (P-007) is a PROTAC-based CBP and p300 degrader (extracted from patent WO2020173440) .

HY-139108

DCH36_06	Histone Acetyltransferase Apoptosis	Cancer
DCH36_06 is a potent and selective *p300/CBP* inhibitor with IC₅₀s of 0.6 μM and 3.2 μM for *p300* and *CBP, respectively. DCH36_06 mediated p300/CBP* inhibition leading to hypoacetylation on H3K18 in leukemic cells. Anti-tumor activity .

HY-136938

NEO2734 1 Publications Verification EP31670	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
NEO2734 (EP31670) is an orally active dual *p300/CBP* and BET bromodomain selective inhibitor, with IC₅₀ values of <30 nM for both p300/CBP and BET bromodomains . NEO2734 is active in SPOP mutant and wild-type prostate cancer .

HY-147261

B026	Histone Acetyltransferase	Cancer
B026 is a selective, potent, orally active p300/CBP histone acetyltransferase (HAT) inhibitor with IC₅₀ values of 1.8 nM and 9.5 nM for p300 and CBP enzyme, respectively. B026 has anticancer activity for androgen receptor-positive (AR+) prostate cancer cell lines .

HY-128761

CBP/p300-IN-2	Epigenetic Reader Domain	Cancer
CBP/EP300-IN-2 is an inhibitor of *CBP/EP300* with IC₅₀ values of 1.07 nM and 5.96 nM for CBP/HTRF and Myc, respectively. CBP/EP300-IN-2, example 25, is extracted from patent WO2017205538A1 .

HY-134591

Thalidomide-NH-PEG4-COOH	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-PEG4-COOH is an E3 ligase ligand-linker conjugate which can be used for synthesizing dCBP-1. dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-134592

Piperidine-GNE-049-N-Boc	Ligands for Target Protein for PROTAC	Cancer
Piperidine-GNE-049-N-Boc is a ligand for target protein for PROTAC of dCBP-1 (HY-134582). dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP .

HY-134582

dCBP-1 3 Publications Verification	PROTACs Epigenetic Reader Domain	Cancer
dCBP-1 is a potent and selective heterobifunctional degrader of *p300/CBP* based on Cereblon ligand. dCBP-1 is exceptionally potent at killing multiple myeloma cells and ablates oncogenic enhancer activity driving MYC expression .

HY-161710

XYD129	PROTACs Epigenetic Reader Domain Histone Acetyltransferase	Cancer
XYD129 is an effective CBP/p300 PROTAC degrader. XYD129 has antiproliferative activity on MV4-11 cell line (IC ₅₀=0.044 μM). XYD129 can be used for the study of acute myeloid leukemia (AML). (Srtucture Note: Pink, *CBP/p300* ligand 5 (HY-161711); Blue, E3 ligase ligand (HY-41547); Black, Linker (HY-40178)) .

HY-136285

CPI-1612	Histone Acetyltransferase	Cancer
CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-107455

A-485 Maximum Cited Publications 52 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
A-485 is a potent and selective catalytic inhibitor of *p300/CBP* with IC₅₀s of 9.8 nM and 2.6 nM for *p300* and *CBP* histone acetyltransferase (HAT), respectively .

HY-168201

MJP6412	PROTACs Histone Acetyltransferase	Cancer
MJP6412 is a potent degrader *p300/CBP, with DC₅₀* of 1.6 and 1.2 nM for p300 and CBP, respectively. MJP6412 plays an important role in cancer research .

HY-19541

I-CBP112 3 Publications Verification	Histone Acetyltransferase Epigenetic Reader Domain	Cancer
I-CBP112 is a specific and potent acetyl-lysine competitive protein-protein interaction inhibitor, that inhibits the *CBP/p300* bromodomains, enhances acetylation by p300.

HY-145386

(S,S)-CPI-1612	Others	Cancer
(S,S)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-136285A

(R,R)-CPI-1612	Others	Cancer
(R,R)-CPI-1612 is the isomer of CPI-1612 (HY-136285), and can be used as an experimental control. CPI-1612 is a highly potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor with an IC₅₀ of 8.1 nM for EP300 HAT. CPI-1612 has an anticancer activity .

HY-161494

XYD190	PROTACs Epigenetic Reader Domain	Cancer
XYD190 (Compound 14g) is an orally active degrader for CBP/p300. XYD190 inhibits CBP/p300 bromodomain with IC₅₀ of 483.7 nM. XYD190 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161496)) .

HY-161498

XYD198	PROTACs Epigenetic Reader Domain	Cancer
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC₅₀ of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 (HY-161495); Blue, E3 ligase ligand (HY-14658); Black: linker (HY-161499))

HY-123758

XDM-CBP	Epigenetic Reader Domain	Cancer
XDM-CBP is a *CBP/p300* inhibitor. XDM-CBP can be used in the study of malignant melanoma, breast cancer and leukemia .

HY-139148

UMB298	Epigenetic Reader Domain	Cancer
UMB298 is a potent and selective *CBP/P300* bromodomain inhibitor .

HY-161369

CBPD-268	PROTACs Histone Acetyltransferase	Cancer
CBPD-268 is a potent and orally active *CBP/p300* PROTAC degrader with an DC₅₀ value of ≤ 0.03 nM. CBPD-268 induces CBP/p300 degradation and inhibits cell growth. CBPD-268 shows antitumor activity. CBPD-268 has the potential for the research of AR-positive prostate cancer (Srtucture Note: Red, Androgen receptor degrader (HY-W248665A); Blue, CBP/p300 ligand (HY-161483); Black, Linker) .

HY-100697

TPOP146 3 Publications Verification	Epigenetic Reader Domain Histone Acetyltransferase	Cancer
TPOP146 is a selective *CBP/P300* benzoxazepine bromodomain inhibitor with K_d values of 134 nM and 5.02 μM for CBP and BRD4.

HY-124696

PU139 3 Publications Verification	Histone Acetyltransferase	Cancer
PU139 is a potent pan-histone acetyltransferase (HAT) inhibitor. PU139 blocks the HATs Gcn5, p300/CBP-associated factor (PCAF), CREB (cAMP response element-binding) protein (CBP) and p300 with IC₅₀s of 8.39, 9.74, 2.49 and 5.35 μM, respectively .

HY-111784

Inobrodib 5+ Cited Publications CCS1477	Epigenetic Reader Domain	Cancer
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with K_d values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a K_d of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression .

HY-149306

MS78	Histone Acetyltransferase MDM-2/p53	Cancer
MS78 is an acetylation targeting chimera (AceTAC) that acetylates the p53 tumor suppressor protein. MS78 recruits histone acetyltransferase *p300/CBP* to acetylate the p53Y220C mutant. MS78 upregulates TRAIL apoptotic genes and downregulates DNA damage response pathways. MS78 contains a CBP/p300 binder, a p53Y220C binder and a linker .

HY-124722

OHM1	HIF/HIF Prolyl-Hydroxylase	Cancer
OHM1 is an analog of HIF1α CTAD that inhibits its binding with p300/CBP. OHM1 targets CH1 domain with an affinity of 0.53 μM .

HY-15826

SGC-CBP30 10+ Cited Publications	Epigenetic Reader Domain Histone Acetyltransferase	Inflammation/Immunology Cancer
SGC-CBP30 is a potent and highly selective CBP/p300 bromodomain (K_ds of 21 nM and 32 nM for *CBP* and *p300, respectively) inhibitor, displaying 40-fold selectivity over the first bromodomain of BRD4 [BRD4(1)]* bound. SGC-CBP30 strongly reduces secretion of IL-17A in Th17 cells and has anti-inflammatory effects .

HY-141546

Pocenbrodib	Histone Acetyltransferase	Cancer
Pocenbrodib (compound II) is a *CBP/p300* family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research .

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

HY-154984

JET-209	Histone Acetyltransferase PROTACs	Cancer
JET-209 is a potent PROTAC *CBP/p300* degrader, with DC₅₀ values of 0.05 nM and 0.2 nM for CBP and p300. JET-209 contains Lenalidomide (HY-A0003) (the cereblon ligand), a linker and GNE-207 (HY-120028) (bromodomain Inhibitor). JET-209 is used for cancer research .

HY-101125A

L-Moses dihydrochloride 2 Publications Verification L-45 dihydrochloride	Epigenetic Reader Domain	Cancer
L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a K_d of 126 nM .

Cat. No.	Product Name	Target	Research Area

HY-P10238

MYBMIM	Apoptosis	Cancer
MYBMIM is an inhibitor for assembly of the molecular *MYB:CBP/P300* complex. MYBMIM inhibits growth of leukemia cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: